Paul M Lieberman

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258314 - EBNA1 inhibitors and their method of use (2025-03-25),

2. 12116359 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2024-10-15),

3. 11912659 - EBNA1 inhibitors and methods using same (2024-02-27),

4. 11242338 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2022-02-08),

5. 11242317 - EBNA1 inhibitors and their method of use (2022-02-08),

6. 10981867 - EBNA1 inhibitors and methods using same (2021-04-20),

7. 10442763 - EBNA1 inhibitors and methods using same (2019-10-15),

8. 10421718 - EBNA1 inhibitors and their method of use (2019-09-24),

9. 10307406 - Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor (2019-06-04),

10. 9856214 - EBNA1 inhibitors and their method of use (2018-01-02),

11. 9309212 - Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1 (2016-04-12),

Sure, here is the article about inventor Paul M Lieberman:

Title: Inventor Spotlight: Paul M Lieberman

Introduction:

Paul M Lieberman, an innovative inventor based in Wynnewood, PA, has made significant contributions to the field of medicine with a focus on developing EBNA1 inhibitors for the treatment of various diseases.

Latest Patents:

Paul M Lieberman's latest patents include "EBNA1 inhibitors and methods using the same." These inhibitors and pharmaceutical compositions are designed to combat diseases caused by EBNA1 activity, such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. Additionally, the inventions target diseases resulting from latent and lytic Epstein-Barr Virus (EBV) infections.

Career Highlights:

Throughout his career, Paul M Lieberman has amassed a total of 9 patents, showcasing his dedication to innovation in the medical field. He has been instrumental in developing novel treatment options for a range of diseases, particularly those associated with EBNA1 activity and EBV infections. Some of the notable companies he has been associated with include The Wistar Institute of Anatomy & Biology and The Wistar Institute.

Collaborations:

Collaboration plays a key role in the success of inventors like Paul M Lieberman. He has worked closely with proficient colleagues such as Troy E Messick and Garry Robert Smith, fostering a culture of innovation and excellence in his research endeavors.

Conclusion:

In conclusion, Paul M Lieberman's groundbreaking work in developing EBNA1 inhibitors underscores his commitment to advancing medical treatments. His innovative approach to addressing diseases caused by EBNA1 activity and EBV infections has the potential to positively impact the lives of many individuals worldwide, making him a noteworthy figure in the realm of medical inventions.

This text is generated by artificial intelligence and may not be accurate.